First, scientists need to know when this pathway behaves as pro- or anti-angiogenic and this different behavior seems to be related to the heterogeneity of tumor blood vessels and the composition of BMPRI (ALK1, ALK2, ALK3 and ALK6) and BMPRII receptors. Here, ACVRL1 is linked to neoplasm.